Can you provide the average price target for INCYTE CORP stock?
33 analysts have analysed INCY and the average price target is 109.32 USD. This implies a price increase of 18.53% is expected in the next year compared to the current price of 92.23.
NASDAQ:INCY • US45337C1027
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INCYTE CORP (INCY).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-25 | UBS | Maintains | Neutral -> Neutral |
| 2026-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-16 | Jefferies | Downgrade | Buy -> Hold |
| 2026-03-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-05 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-18 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-11 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-11 | Stifel | Maintains | Buy -> Buy |
| 2026-02-11 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-05 | HC Wainwright & Co. | Initiate | Buy |
| 2026-02-04 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-20 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2026-01-13 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-08 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-12-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-08 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-11-03 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-10-29 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-10-29 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.696B 8.87% | 4.241B 14.76% | 5.141B 21.22% | 5.705B 10.97% | 6.303B 10.48% | 6.482B 2.84% | 4.712B -27.31% | 4.869B 3.33% | 5.531B 13.60% | 5.818B 5.19% | 6.05B 3.99% | |
| EBITDA YoY % growth | 734.432M 10.04% | 200.892M -72.65% | 1.436B 614.83% | 1.949B 35.72% | 2.497B 28.12% | 2.682B 7.41% | 1.212B -54.81% | 1.013B -16.42% | 1.069B 5.53% | 1.105B 3.37% | 1.148B 3.89% | |
| EBIT YoY % growth | 651.772M 8.72% | 111.644M -82.87% | 1.343B 1,102.71% | 1.924B 43.29% | 2.401B 24.79% | 2.589B 7.83% | 799.78M -69.11% | 1.169B 46.17% | 1.939B 65.87% | 2.258B 16.45% | 2.492B 10.36% | |
| Operating Margin | 17.64% | 2.63% | 26.12% | 33.72% | 38.09% | 39.94% | 16.97% | 24.01% | 35.06% | 38.81% | 41.19% | |
| EPS YoY % growth | 3.52 26.62% | 1.32 -62.50% | 6.79 414.39% | 7.66 12.80% | 8.98 17.21% | 9.60 6.96% | 3.92 -59.16% | 4.41 12.36% | 7.16 62.43% | 8.10 13.20% | 8.81 8.79% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.46 25.72% | 1.82 15.62% | 2.17 -4.01% | 2.36 31.26% |
| Revenue Q2Q % growth | 1.275B 21.09% | 1.405B 15.59% | 1.464B 7.18% | 1.545B 2.53% |
| EBITDA Q2Q % growth | 268.75M 12.40% | 418.21M 17.44% | 628.89M 25.62% | 616.55M 29.21% |
| EBIT Q2Q % growth | 358.26M 65.29% | 460.63M 48.20% | 726.58M 68.46% | 682.61M 77.82% |
All data in USD
33 analysts have analysed INCY and the average price target is 109.32 USD. This implies a price increase of 18.53% is expected in the next year compared to the current price of 92.23.
INCYTE CORP (INCY) will report earnings on 2026-04-27.
The consensus EPS estimate for the next earnings of INCYTE CORP (INCY) is 1.46 USD and the consensus revenue estimate is 1.27B USD.
The expected long term growth rate for INCYTE CORP (INCY) is 8.5%.